

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

PE/Dazzle(TM) 594 anti-human CD3

RRID:AB_2563618

Type: Antibody

Proper Citation

BioLegend Cat# 300450, RRID:AB_2563618

Antibody Information

URL: http://antibodyregistry.org/AB_2563618

Proper Citation: BioLegend Cat# 300450, RRID:AB_2563618

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Dazzle(TM) 594 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_2563618

Vendor: BioLegend

Catalog Number: 300450

Alternative Catalog Numbers: 300449

Record Creation Time: 20250820T061733+0000

Record Last Update: 20250820T234303+0000

Ratings and Alerts

No rating or validation information has been found for PE/Dazzle(TM) 594 anti-human CD3.

No alerts have been found for PE/Dazzle(TM) 594 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Li H, et al. (2025) Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. *Cancer cell*, 43(4), 757.

Neuwirth T, et al. (2025) The polyamine-regulating enzyme SSAT1 impairs tissue regulatory T cell function in chronic cutaneous inflammation. *Immunity*, 58(3), 632.

Patel E, et al. (2024) XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies. *Molecular cancer therapeutics*, 23(4), 421.

Krausgruber T, et al. (2023) Single-cell and spatial transcriptomics reveal aberrant lymphoid developmental programs driving granuloma formation. *Immunity*, 56(2), 289.

Luoma AM, et al. (2022) Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. *Cell*, 185(16), 2918.

Höfle J, et al. (2022) Engagement of TRAIL triggers degranulation and IFN γ production in human natural killer cells. *EMBO reports*, 23(8), e54133.

Biermann J, et al. (2022) Dissecting the treatment-naïve ecosystem of human melanoma brain metastasis. *Cell*, 185(14), 2591.

Krämer B, et al. (2021) Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. *Immunity*, 54(11), 2650.

Luoma AM, et al. (2020) Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. *Cell*, 182(3), 655.

De Domenico E, et al. (2020) Optimized workflow for single-cell transcriptomics on infectious diseases including COVID-19. *STAR protocols*, 1(3), 100233.

Schulte-Schrepping J, et al. (2020) Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. *Cell*, 182(6), 1419.